CD22 and non-Hodgkin lymphoma: Therefore, the IT was further evaluated in a phase I trial (CTI: NCT00126646) on 46 CD22+ patients (four non-Hodgkin’s lymphoma (NHL), 11 chronic lymphocytic leukemia (CLL), and 31 HCL).